
Opinion|Videos|April 28, 2025
Presenting the Treatment Options in EGFR-Mutant NSCLC: Weighing the Data and Incorporating the Patient Perspective
Panelists discuss how conversations with patients about treatment options have become more complex and nuanced, requiring thorough explanation of efficacy data and adverse effects while adapting to each patient’s level of understanding and involvement.
Advertisement
Episodes in this series

Video content above is prompted by the following:
Communication Strategies for Treatment Decision-Making
Key Themes:
- Shared Decision-Making: Challenges in presenting complex clinical trial data to patients in time-constrained clinical settings
- Patient Education: Balancing efficacy outcomes with toxicity profiles when discussing treatment options
- Individualized Approach: Recognizing that patient preferences and knowledge vary significantly
Notable Insights:
- Dr Piotrowska: “I think the best way to do this is to try to talk about it and then give patients a little bit of time to digest and think through these options, and maybe not make a final decision in that initial visit.” She also acknowledges that clinicians bring their own biases to these conversations.
- Dr Dietrich: Notes the importance of recognizing different patient information needs, stating “Some patients are very informed...and some others are deferring more to me.” He emphasized that these discussions have become “significantly harder, both on the discussion about efficacy and the nuances of [adverse] effects.”
Advertisement
Related to this article

The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.

Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement
Trending on OncLive
1
Dr Gleave on Selecting Patients for Perioperative Therapy in High-Risk Prostate Cancer
2
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
3
Mirdametinib Deepens Responses in NF1-Associated Plexiform Neurofibroma
4
Cross Currents: New Frontiers in ADC Therapy for Breast Cancer
5

